Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: The ODYSSEY ESCAPE trial

European Heart Journal

Volumn 37, Issue 48, 2016, Pages 3588-3595

  Moriarty, Patrick M ^a   Parhofer, Klaus G ^b   Babirak, Stephan P ^c   Cornier, Marc Andre ^d   Duell, P Barton ^e   Hohenstein, Bernd ^f   Leebmann, Josef ^g   Ramlow, Wolfgang ^h   Schettler, Volker ⁱ   Simha, Vinaya ^j   Steinhagen Thiessen, Elisabeth ^k   Thompson, Paul D ^l   Vogt, Anja ^b   Von Stritzky, Berndt ^m   Du, Yunling ⁿ   Manvelian, Garen ^o  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Metabolic Leader LLC   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g Apherese Zentrum Passau   (Germany)

^h Apheresis Centrum Rostock   (Germany)

ⁱ Apheresis Centre   (Germany)

^j MAYO CLINIC   (United States)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l HARTFORD HOSPITAL   (United States)

^m SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

ⁿ REGENERON PHARMACEUTICALS INC   (United States)

^o REGENERON PHARMACEUTICALS INC   (United States)

more..

Author keywords

Alirocumab; Familial hypercholesterolaemia; Low density lipoprotein cholesterol; Low density lipoprotein receptor; Monoclonal antibody; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; CREATINE KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PLACEBO; PROPROTEIN CONVERTASE 9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN;

ACUTE HEART INFARCTION; ACUTE RESPIRATORY FAILURE; ADULT; AORTIC VALVE STENOSIS; APHERESIS; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; LIPOPROTEIN APHERESIS; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS; TREATMENT OUTCOME;

EID: 85014503636     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw388     Document Type: Article

References (22)

1. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statintreated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008;29:2625-2633.
2. Rosada A, Kassner U, Banisch D, Bender A, Steinhagen-Thiessen E, Vogt A. Quality of life in patients treated with lipoprotein apheresis. J Clin Lipidol 2016;10:323-329.e6.
3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
4. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm 2013;19:139-149.
5. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014;176:55-61.
6. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM, ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015;36:1186-1194.
7. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I, Robinson J, Zhao J, Hanotin C, Donahue S. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab 2015;100:3140-3148.
8. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J 2015;169:906-915 e13.
9. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015;36:2996-3003.
10. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-1900.
11. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-2353.
12. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-1499.
13. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
14. Moriarty PM, Parhofer KG, Babirak SP, deGoma E, Duell PB, Hohenstein B, Ramlow W, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: rationale and design of the ODYSSEY ESCAPE trial. J Clin Lipidol 2016;10:627-634.
15. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-896.
16. World Health Organization. Familial Hypercholesterolemia (FH). Report of a second WHO Consultation. http://whqlibdoc.who.int/hq/1999/WHO-HGN-FH-CONS-99.2.pdf?ua=1; 1998, 16 (20 July 2016).
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Kroon AA, Van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000;152:519-526.
19. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System. Cary, NC: SAS Institute Inc.; 2000.
20. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm 2013;19:139-149.
21. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014;129:S1-45.
22. Lappegard KT, Enebakk T, Thunhaug H, Hovland A. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol. Atherosclerosis 2016;251:119-123.